S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
CVE:PAS

Pascal Biosciences Stock Forecast, Price & News

C$0.08
+0.01 (+6.25 %)
(As of 10/14/2021 03:54 PM ET)
Add
Compare
Today's Range
C$0.08
C$0.09
50-Day Range
C$0.08
C$0.10
52-Week Range
C$0.08
C$0.16
Volume26,750 shs
Average Volume79,682 shs
Market CapitalizationC$5.53 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PAS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pascal Biosciences and its competitors with MarketBeat's FREE daily newsletter.


About Pascal Biosciences

Pascal Biosciences Inc., a biotechnology company, researches and develops products for the treatment of cancer, and for the enhancement of immune system. Its development portfolio includes PAS-403, a small molecule therapeutic advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy for cancer treatment. The company is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was founded in 2013 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
6
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.00 per share
Book Value
C$0.00 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
C$5.53 million
Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.96 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Pascal Biosciences (CVE:PAS) Frequently Asked Questions

What stocks does MarketBeat like better than Pascal Biosciences?

Wall Street analysts have given Pascal Biosciences a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pascal Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Pascal Biosciences' stock price been impacted by COVID-19?

Pascal Biosciences' stock was trading at C$0.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PAS stock has decreased by 15.0% and is now trading at C$0.09.
View which stocks have been most impacted by COVID-19
.

Who are Pascal Biosciences' key executives?

Pascal Biosciences' management team includes the following people:
  • Dr. Patrick W. Gray, CEO & Director (Age 69, Pay $223.48k)
  • Mr. Kevin M. Egan M.B.A., Chief Bus. Officer
  • Mr. Mark Adrian Van der Horst, Pres (Age 54)
  • Mr. Harold H. Forzley C.A., Chief Financial Officer (Age 68)

What other stocks do shareholders of Pascal Biosciences own?

What is Pascal Biosciences' stock symbol?

Pascal Biosciences trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PAS."

How do I buy shares of Pascal Biosciences?

Shares of PAS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Pascal Biosciences' stock price today?

One share of PAS stock can currently be purchased for approximately C$0.09.

How much money does Pascal Biosciences make?

Pascal Biosciences has a market capitalization of C$5.53 million.

How many employees does Pascal Biosciences have?

Pascal Biosciences employs 6 workers across the globe.

What is Pascal Biosciences' official website?

The official website for Pascal Biosciences is www.biommune.net.

Where are Pascal Biosciences' headquarters?

Pascal Biosciences is headquartered at 400 Burrard St Suite 1780, VANCOUVER, BC V6C 3A6, Canada.

How can I contact Pascal Biosciences?

Pascal Biosciences' mailing address is 400 Burrard St Suite 1780, VANCOUVER, BC V6C 3A6, Canada. The company can be reached via phone at +1-604-6886775.


This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.